GridAI Technologies Corp. Files 8-K with Key Corporate Updates

TL;DR

GridAI filed an 8-K on Nov 28, 2025, reporting material agreements, exec changes, and bylaw amendments. Big moves happening.

AI Summary

GridAI Technologies Corp. filed an 8-K on December 4, 2025, reporting several key events as of November 28, 2025. These include entering into a material definitive agreement, changes in directors and officers, amendments to its articles of incorporation or bylaws, and other events. The company, formerly known as Entero Therapeutics, Inc., First Wave BioPharma, Inc., and AzurRx BioPharma, Inc., is incorporated in Delaware and has its principal executive offices in Boca Raton, Florida.

Why It Matters

This 8-K filing signals significant corporate actions and potential strategic shifts for GridAI Technologies Corp., which could impact its business operations and investor outlook.

Risk Assessment

Risk Level: medium — The filing indicates significant corporate changes, including material agreements and executive/director shifts, which can introduce uncertainty and potential risks.

Key Players & Entities

• GridAI Technologies Corp. (company) — Filer
• Entero Therapeutics, Inc. (company) — Former company name
• First Wave BioPharma, Inc. (company) — Former company name
• AzurRx BioPharma, Inc. (company) — Former company name
• November 28, 2025 (date) — Date of earliest event reported
• December 4, 2025 (date) — Filing date

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share GRDX The Nasdaq Stock Mar
• $500,000 — , the Company agreed to pay Mr. Paolone $500,000 along with his legal fees in connection

Filing Documents

• tm2532710d1_8k.htm (8-K) — 37KB
• tm2532710d1_ex3-1.htm (EX-3.1) — 6KB
• tm2532710d1_ex10-1.htm (EX-10.1) — 102KB
• tm2532710d1_ex99-1.htm (EX-99.1) — 5KB
• tm2532710d1_ex99-2.htm (EX-99.2) — 8KB
• 0001104659-25-118524.txt ( ) — 355KB
• grdx-20251128.xsd (EX-101.SCH) — 3KB
• grdx-20251128_lab.xml (EX-101.LAB) — 33KB
• grdx-20251128_pre.xml (EX-101.PRE) — 22KB
• tm2532710d1_8k_htm.xml (XML) — 4KB

01. Entry into a Material Definitive

Item 1.01. Entry into a Material Definitive Agreement. The information set forth below under Item 5.02 of this Current Report on Form 8-K relating to the Separation Agreement is hereby incorporated into this

01 by reference

Item 1.01 by reference.

02. Departure

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Mr. Eric Corbett as a director of the Company: On November 28, 2025, Mr. Eric Corbett notified the Company of his resignation as a director of GridAI Technologies Corp. (f/k/a Entero Therapeutics, Inc.) (the "Company"). Mr. Corbett's resignation was a result of disagreements with members of the Company's management and Board of Directors of the Company (the "Board") related to certain governance policies and practices, including concerns relating to public disclosures, due diligence and corporate governance. A copy of such correspondence is attached as Exhibit 99.1 hereto and is incorporated by reference herein. Resignation of Mr. Richard Paolone as a director of the Company: On November 28, 2025, Mr. Richard Paolone notified the Company of his resignation as a director of the Company. Mr. Paolone's resignation was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. Separation Agreement and Mutual Release: In connection with Mr. Paolone's departure, the Company entered into a Separation Agreement and Mutual Release with Mr. Paolone and 2818390 Ontario Corp., an Ontario, Canada corporation on November 28, 2025 (the "Separation Agreement"). Under the Separation Agreement, the Company agreed to pay Mr. Paolone $500,000 along with his legal fees in connection with the entry into the Separation Agreement. The summary of the Separation Agreement set forth above is qualified in its entirety by reference to the full text of the Separation Agreement, which is attached as Exhibit 10.1 hereto and incorporated herein by reference. Pursuant to the resignations of directors discussed in this Item 5.02, the committees of the Board of Directors of the Company shall comprise of the following: (a) Audit Committee: (i) Ed Borkows

01. Other Events

Item 8.01. Other Events In connection with the Name Change, the Board also approved the change of the trading symbol for the Company's common stock on The Nasdaq Capital Market from "ENTO" to "GRDX" (the "Symbol Change"). The Company's common stock began to trade under the new name and trading symbol as of the commencement of trading on December 1, 2025. The CUSIP number for the Company's common stock did not change in connection with the Name Change. On November 28, 2025, the Company issued a press release announcing the name change and trading symbol change. The press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference, except that the information contained on any websites referenced in the press release is not incorporated by reference.

01 Financial

Item 9.01 Financial (d) Exhibits . Exhibit No. Description 3.1 Certificate of Amendment to Restated Certificate of Incorporation 10.1 Separation Agreement and Mutual Release dated November 28, 2025 between the Company, Richard Paolone and 2818390 Ontario Corp. 99.1 Resignation letter of Eric Corbett, dated November 28, 2025 99.2 Press Release, dated November 28, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entero Therapeutics, Inc. December 4, 2025 By: /s/ Jason D. Sawyer Name: Jason D. Sawyer Title: Interim Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR